Mobile

A two-year extension to a one-year, multicenter, partially blinded, double-dummy, randomized study to evaluate the efficacy and safety of FTY720 combined with reduced-dose or full-dose Neoral and cort...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004377-28

A two-year extension to a one-year, multicenter, partially blinded, double-dummy, randomized study to evaluate the efficacy and safety of FTY720 combined with reduced-dose or full-dose Neoral and corticosteroids versus mycophenolate mofetil (MMF, CellCept) combined with full-dose Neoral and corticosteroids, in de novo adult renal transplant recipients

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The purpose of this two-year extension is to allow patients who have completed the one-year core study to continue treatment with FTY720 or MMF in combination with reduced or full-dose Neoral (per randomized treatment assignment) beyond the first year post-transplantation for a total of three years follow-up.

Critère d'inclusion

  • Prophylaxis of kidney allograft rejection in de novo adult renal transplant recipients

Liens